H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Anavex to $50 from $42 and keeps a Buy rating on the shares. The analyst says pivotal clinical data for blarcamesine in Alzheimer’s disease "shows promise."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AVXL:
- Anavex appoints Grimmer to Scientific Advisory Board
- Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial
- Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Unusually active option classes on open December 6th
- Anavex downgraded to Neutral from Overweight at Cantor Fitzgerald